Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials

被引:9
作者
Robinson, Donald W., Jr. [1 ]
Zhao, Ning [1 ]
Dawkins, Fitzroy [2 ]
Qi, Ming [2 ]
Revicki, Dennis [3 ]
机构
[1] Janssen Global Serv LLC, Malvern, PA 19355 USA
[2] Janssen Res & Dev LLC, Spring House, PA USA
[3] United BioSource Corp, Bethesda, MD USA
关键词
Prostate cancer; Pain; Symptoms; Psychometrics; Epidemiology; Quality of life; QUALITY-OF-LIFE; END-POINTS; FUNCTIONAL ASSESSMENT; MONOCLONAL-ANTIBODY; RANDOMIZED-TRIALS; OPEN-LABEL; MITOXANTRONE; DOCETAXEL; SURVIVAL; MEN;
D O I
10.1007/s11136-013-0411-z
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose To compare pain assessment questionnaires commonly used in advanced prostate cancer trials and to determine the psychometric characteristics and longitudinal relationships by contrasting questionnaire data from two international phase 2 trials. Methods Scores from the Present Pain Intensity (PPI) question of the McGill Pain Questionnaire, the pain intensity scale of the Brief Pain Inventory (BPI), and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) were analyzed using Pearson correlation, intra-class correlation coefficient, and Cronbach's alpha, respectively. Concordance was evaluated with Cohen's kappa coefficient and McNemar test at baseline (n = 224) and two subsequent observations. Results PPI and FACT-P scores were associated with the BPI score at baseline for Trials 1 and 2: PPI r = 0.66 and 0.80, respectively (P < 0.001); FACT-P (pain scale) r = -0.76 and -0.82, respectively (P < 0.001). However, concordance analysis revealed that the BPI identified pain (score > 0) at higher rates than the PPI: at baseline, BPI: 89 % (64/72) and 77 % (95/124), PPI: 68 % (49/72) and 64 % (79/124) [Trials 1 and 2, respectively; McNemar test (P < 0.001) for both studies]. The FACT-P pain scale identified pain similarly to the BPI pain intensity scale; longitudinal analysis produced comparable findings. All pain scales met standard psychometric acceptability criteria, but the BPI and FACT-P performed better than the PPI. Conclusions Data suggest the BPI pain intensity and FACT-P pain scales are better than the PPI question at capturing the pain experience among patients with advanced prostate cancer. Additional comparative research is needed in larger population samples.
引用
收藏
页码:2777 / 2786
页数:10
相关论文
共 51 条
[1]   Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma - Results of Intergroup 0159/Cancer and Leukemia Group B 9480 [J].
Ahles, TA ;
Herndon, JE ;
Small, EJ ;
Vogelzang, NJ ;
Kornblith, AB ;
Ratain, MJ ;
Stadler, W ;
Palchak, D ;
Marshall, ME ;
Wilding, G ;
Petrylak, D ;
Holland, JC .
CANCER, 2004, 101 (10) :2202-2208
[2]   A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis [J].
Armstrong, Andrew J. ;
Garrett-Mayer, Elizabeth S. ;
Yang, Yi-Chun Ou ;
de Wit, Ronald ;
Tannock, Ian F. ;
Eisenberger, Mario .
CLINICAL CANCER RESEARCH, 2007, 13 (21) :6396-6403
[3]   Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer [J].
Armstrong, Andrew J. ;
Garrett-Mayer, Elizabeth ;
Yang, Yi-Chun Ou ;
Carducci, Michael A. ;
Tannock, Ian ;
de Wit, Ronald ;
Eisenberger, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3965-3970
[4]   The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial Endpoint Considerations [J].
Atkinson, Thomas M. ;
Mendoza, Tito R. ;
Sit, Laura ;
Passik, Steven ;
Scher, Howard I. ;
Cleeland, Charles ;
Basch, Ethan .
PAIN MEDICINE, 2010, 11 (03) :337-346
[5]   Prostate cancer pain management: EAU guidelines on pain management [J].
Bader, Pia ;
Echtle, Dieter ;
Fonteyne, Valerie ;
Livadas, Kostas ;
De Meerleer, Gert ;
Paez Borda, Alvaro ;
Papaioannou, Eleni G. ;
Vranken, Jan H. .
WORLD JOURNAL OF UROLOGY, 2012, 30 (05) :677-686
[6]  
Basch EM, 2009, J CLIN ONCOL, V27
[7]   Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone [J].
Berry, Donna L. ;
Moinpour, Carol M. ;
Jiang, Caroline S. ;
Ankerst, Donna Pauler ;
Petrylak, Daniel P. ;
Vinson, Lynne V. ;
Lara, Primo N. ;
Jones, Sharon ;
Taplin, Mary E. ;
Burch, Patrick A. ;
Hussain, Maha H. A. ;
Crawford, E. David .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2828-2835
[8]   Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study [J].
Berthold, Dominik R. ;
Pond, Gregory R. ;
Roessner, Martin ;
de Wit, Ronald ;
Eisenberger, Mario ;
Tannock, Ian F. .
CLINICAL CANCER RESEARCH, 2008, 14 (09) :2763-2767
[9]   Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy-Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer [J].
Cella, David ;
Nichol, Michael B. ;
Eton, David ;
Nelson, Joel B. ;
Mulani, Parvez .
VALUE IN HEALTH, 2009, 12 (01) :124-129
[10]   A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer [J].
Chu, Franklin M. ;
Picus, Joel ;
Fracasso, Paula M. ;
Dreicer, Robert ;
Lang, Zhihui ;
Foster, Brenda .
INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) :674-679